Miebo
(Perfluorohexyloctane)Phase 2Small molecule
Miebo is one of 38 small molecule programs targeting Eye Disease. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
37
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
6
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
200 competitors in Eye Disease
#DrugCompanyPhaseTrials
1Neoral
NovartisPhase 3
Alphagan
AbbViePhase 3
Chantix
PfizerPhase 3
Bayer Aspirin
BayerPhase 3
Zovirax
BBp Consulting, Inc
Phase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
CF101
CCan-Fite BioPharma
Phase 3
Carboxymethylcellulose
AbbViePhase 3
Refresh Plus
AbbViePhase 3
Cenegermin
DDompé Farmaceutici S.p.A
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
May 18, 2023
MIEBO
NDA NDA216675
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Perfluorohexyloctane. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]FDA Orange Book — Patent and exclusivity data for Miebo. U.S. Food & Drug Administration.
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBausch Health Americas, Inc.